{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Allogeneic+stem+cell+transplantation&page=7",
    "query": {
      "intervention": "Allogeneic stem cell transplantation",
      "page": 7
    },
    "page_size": 10
  },
  "pagination": {
    "page": 7,
    "page_size": 10,
    "total_count": 1997,
    "total_pages": 200,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Allogeneic+stem+cell+transplantation&page=8&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Allogeneic+stem+cell+transplantation&page=6&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-08T18:43:41.208Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01105650",
      "title": "Allogeneic Natural Killer (NK) Cells for Ovarian, Fallopian Tube, Peritoneal and Metastatic Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ovarian Cancer",
        "Fallopian Tube Cancer",
        "Primary Peritoneal Cancer",
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Cyclosporine",
          "type": "DRUG"
        },
        {
          "name": "Natural killer cells",
          "type": "BIOLOGICAL"
        },
        {
          "name": "IL-2",
          "type": "DRUG"
        },
        {
          "name": "Methylprednisolone",
          "type": "DRUG"
        },
        {
          "name": "Interleukin-2",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Masonic Cancer Center, University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 13,
      "start_date": "2010-07",
      "completion_date": "2014-04",
      "has_results": true,
      "last_update_posted_date": "2017-12-28",
      "last_synced_at": "2026-10-08T18:43:41.208Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01105650"
    },
    {
      "nct_id": "NCT00638820",
      "title": "Reduced Intensity AlloTransplant For Osteopetrosis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Osteopetrosis"
      ],
      "interventions": [
        {
          "name": "Stem Cell or Umbilical Cord Blood Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Campath, Busulfan, Clofarabine",
          "type": "DRUG"
        },
        {
          "name": "Total Lymphoid Irradiation",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "Masonic Cancer Center, University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "Up to 45 Years"
      },
      "enrollment_count": 3,
      "start_date": "2007-09",
      "completion_date": "2008-05",
      "has_results": true,
      "last_update_posted_date": "2017-12-28",
      "last_synced_at": "2026-10-08T18:43:41.208Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00638820"
    },
    {
      "nct_id": "NCT01562158",
      "title": "Efficacy and Safety of Activated Recombinant Human Factor VII in Treatment of Bleeding in Patients Following Allogeneic Stem Cell Transplantation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acquired Bleeding Disorder",
        "Bleeding During/Following Surgery"
      ],
      "interventions": [
        {
          "name": "standard therapy",
          "type": "PROCEDURE"
        },
        {
          "name": "activated recombinant human factor VII",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "Novo Nordisk A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2001-04",
      "completion_date": "2003-10",
      "has_results": false,
      "last_update_posted_date": "2017-01-11",
      "last_synced_at": "2026-10-08T18:43:41.208Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01562158"
    },
    {
      "nct_id": "NCT04171843",
      "title": "A Dose-escalation Study to Evaluate the Safety and Clinical Activity of PBCAR269A, With or Without Nirogacestat, in Study Participants With Relapsed/Refractory Multiple Myeloma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Relapsed/Refractory Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "PBCAR269A",
          "type": "GENETIC"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Nirogacestat",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "GENETIC",
        "DRUG"
      ],
      "sponsor": "Precision BioSciences, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 48,
      "start_date": "2020-04-30",
      "completion_date": "2022-10-19",
      "has_results": false,
      "last_update_posted_date": "2023-09-21",
      "last_synced_at": "2026-10-08T18:43:41.208Z",
      "location_count": 5,
      "location_summary": "Duarte, California • San Francisco, California • Boston, Massachusetts + 2 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04171843"
    },
    {
      "nct_id": "NCT04428476",
      "title": "Open-label Extension of the HOPE-2 Trial",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Duchenne Muscular Dystrophy"
      ],
      "interventions": [
        {
          "name": "Deramiocel (CAP-1002)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Capricor Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "10 Years and older"
      },
      "enrollment_count": 13,
      "start_date": "2020-08-05",
      "completion_date": "2027-03",
      "has_results": true,
      "last_update_posted_date": "2026-09-22",
      "last_synced_at": "2026-10-08T18:43:41.208Z",
      "location_count": 5,
      "location_summary": "Sacramento, California • Aurora, Colorado • St Louis, Missouri + 2 more",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04428476"
    },
    {
      "nct_id": "NCT02479698",
      "title": "Cytotoxic T Lymphocytes in Treating Patients With Malignancies With BK and/or JC Virus",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acquired Immunodeficiency Syndrome",
        "BK Virus Infection",
        "Human Immunodeficiency Virus",
        "JC Virus Infection",
        "Malignant Neoplasm",
        "Merkel Cell Carcinoma",
        "Merkel Cell Polyomavirus Infection",
        "Viral Encephalitis"
      ],
      "interventions": [
        {
          "name": "Allogeneic BK-specific Cytotoxic T-lymphocytes",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 100,
      "start_date": "2015-07-23",
      "completion_date": "2027-07-31",
      "has_results": false,
      "last_update_posted_date": "2026-09-04",
      "last_synced_at": "2026-10-08T18:43:41.208Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02479698"
    },
    {
      "nct_id": "NCT00556452",
      "title": "Study of Stem Cell Transplantation for Hematologic Malignancies Using Clofarabine and Busulfan Regimen",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Leukemia",
        "Hodgkin Lymphoma",
        "Non-Hodgkin Lymphoma",
        "Multiple Myeloma",
        "Myelodysplastic Syndrome"
      ],
      "interventions": [
        {
          "name": "Clofarabine/Busulfan x 4",
          "type": "DRUG"
        },
        {
          "name": "Peripheral blood stem cell transplant",
          "type": "PROCEDURE"
        },
        {
          "name": "Total Lymphoid Irradiation",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "RADIATION"
      ],
      "sponsor": "University of Michigan Rogel Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "Up to 70 Years"
      },
      "enrollment_count": 46,
      "start_date": "2007-10",
      "completion_date": "2012-09",
      "has_results": true,
      "last_update_posted_date": "2017-12-05",
      "last_synced_at": "2026-10-08T18:43:41.208Z",
      "location_count": 1,
      "location_summary": "Ann Arbor, Michigan",
      "locations": [
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00556452"
    },
    {
      "nct_id": "NCT03451916",
      "title": "Treatment of Muscle Injury Following Arthroplasty for Hip Fracture (HF)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hip Fracture"
      ],
      "interventions": [
        {
          "name": "PLX-PAD",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pluristem Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "0 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "0 Years to 90 Years"
      },
      "enrollment_count": 240,
      "start_date": "2018-07-26",
      "completion_date": "2023-09-06",
      "has_results": false,
      "last_update_posted_date": "2023-09-28",
      "last_synced_at": "2026-10-08T18:43:41.208Z",
      "location_count": 3,
      "location_summary": "Sacramento, California • Denver, Colorado • Indiana, Pennsylvania",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Indiana",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03451916"
    },
    {
      "nct_id": "NCT04392206",
      "title": "AMSC for Reducing Anastomotic Stenosis in Primary Arteriovenous Anastomoses",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "End Stage Renal Disease"
      ],
      "interventions": [
        {
          "name": "Adipose Derived Mesenchymal Stem Cells",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Houssam Farres, M.D.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 15,
      "start_date": "2020-05-15",
      "completion_date": "2027-06",
      "has_results": false,
      "last_update_posted_date": "2026-07-10",
      "last_synced_at": "2026-10-08T18:43:41.208Z",
      "location_count": 1,
      "location_summary": "Jacksonville, Florida",
      "locations": [
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04392206"
    },
    {
      "nct_id": "NCT06208878",
      "title": "A Long-term Follow-up Study of Subjects Who Received CRISPR CAR T Cellular Therapies",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Hematologic Malignancy",
        "Solid Malignancy"
      ],
      "interventions": [
        {
          "name": "Non Interventional",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "CRISPR Therapeutics AG",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 70,
      "start_date": "2023-11-22",
      "completion_date": "2038-08",
      "has_results": false,
      "last_update_posted_date": "2026-09-24",
      "last_synced_at": "2026-10-08T18:43:41.208Z",
      "location_count": 17,
      "location_summary": "Duarte, California • Los Angeles, California • Stanford, California + 14 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06208878"
    }
  ]
}